- Research History -

Our Roots in Infectious Disease Research

NAEJA RGM PHARMACEUTICALS

NAEJA-RGM Pharmaceuticals was established in June 2016 and is building on a lifetime of success that began in 1987 with Dr. Ronald G. Micetich and SynPhar Laboratories Inc.

The NAEJA-RGM scientific team today consists of researchers who spent their careers, 30+ years of research, working and training under Dr. Ronald G. Micetich at SynPhar Laboratories and then NAEJA Pharmaceutical Inc. They were amongst the original employees involved in Dr. Ronald G. Micetich’s drug discovery initiatives and were instrumental in NAEJA's most successful medical research.

RESEARCH CONTRIBUTIONS

Inventors of Mofezolac Sales of $100 million annually		Inventors of Mofezolac Sales of $100 million annually
Inventors of Tazobactam a discovery then paired with Piperacillin and sold as Zosyn, with ongoing sales of $1 billion annually		Inventors of Tazobactam a discovery then paired with Piperacillin and sold as Zosyn, with ongoing sales of $1 billion annually
World Leaders in antibiotic drug discovery		World Leaders in antibiotic drug discovery
Own +120 “Composition of Matter” patents		Own +120 “Composition of Matter” patents
+50 published patents (clients)		+50 published patents (clients)
+50 successful client programs		+50 successful client programs

Publications in the therapeutic areas of anti-infectives, CNS, inflammation, dermatology, cancer and cardiovascular

A HISTORY OF SUCCESS

NAEJA-RGM Pharmaceutical is proud of our founder and the scientific research teams that over the years have contributed so much to the global body of research. We are continuing the successes started by Dr. Ronald G. Micetich and by NAEJA Pharmaceuticals and its predecessors.

Drug-Resistant-Bacteria Infectious-Disease